Itamar Medical and BioTel Heart, a Division of BioTelemetry, Expand Collaboration to Offer Itamar’s Total Sleep Solution™...
June 04 2019 - 7:30AM
Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that
develops, manufacturers and markets non-invasive diagnostic devices
for sleep apnea with a focus on the cardiology market, and BioTel
Heart, a division of BioTelemetry, Inc. (NASDAQ:BEAT), the leading
remote medical technology company focused on the delivery of health
information to improve quality of life and reduce cost of care,
today announced an expanded collaboration to make Itamar Medical’s
Total Sleep Solution available to select BioTel Heart cardiology
customers in the United States. The companies conducted a
successful pilot program with several BioTel Heart customers and
are making the service available in additional targeted regions.
The collaboration is designed to respond to the growing demand for
home sleep apnea testing among cardiologists, who recognize
effective sleep apnea management as a critical strategy for
improving health in patients with cardiac disease.
Itamar Medical’s Total Sleep Solution is a
comprehensive program that combines products and services,
including the company’s innovative diagnostic test, the WatchPAT™.
It is designed to provide cardiologists who are not board certified
in sleep easy access to a comprehensive suite of products and
services, including a network of sleep physicians, for quick,
cost-effective, diagnosis, treatment and management of patients
they suspect suffer from sleep apnea. Products and services in the
Total Sleep Solution program include the WatchPAT, CloudPAT™ and
SleePATh™ for cloud-based data and information mobilization
solutions, and continuous positive airway pressure (CPAP) therapy
compliance monitoring and logistical solutions such as WatchPAT
Direct™.
BioTelemetry is advancing health by providing
technology and services that enable healthcare providers to monitor
and diagnose patients and clinical research subjects in a more
efficient, accurate and cost-effective manner. It is one of the
largest and fastest growing connected health companies. BioTel
Heart processes over four billion heartbeats per day and monitors
over one million patients each year. It is the pioneer in remote
patient monitoring, revolutionizing healthcare with its suite of
cardiac monitoring devices, including its FDA-cleared ePatch™ and
Mobile Cardiac Outpatient Telemetry (MCOT™) monitors.
“We are excited to collaborate with BioTel Heart as
we seek to leverage the growing opportunities for our WatchPAT
technology,” said Gilad Click, President and Chief Executive
Officer of Itamar Medical. “BioTel Heart has an extensive and
trusted network across the cardiology community and a significant
footprint in the U.S. Our collaboration provides the framework for
cardiologists to prescribe home sleep apnea tests without worrying
about pre-authorization and billing. This next step in our strategy
simplifies the integration of our Total Sleep Solution offering
into routine cardiac care pathways.”
“Our collaboration with Itamar Medical creates a
unique opportunity to provide the cardiology community access to
proven sleep apnea technology and services they can leverage while
caring for patients,” said Andy Broadway, President of BioTel
Heart. “Cardiologists recognize that effective home sleep apnea
testing and management can lead to improved patient outcomes and
Itamar Medical’s Total Sleep Solution is an effective and
convenient way to expand access to the tools that help make that
possible.”
“It is estimated that more than half of all
patients with cardiovascular disease suffer from sleep apnea, a
co-morbidity that has significant health and economic impacts,”
said Rodney Horton, M.D., F.A.C.C. (Fellow of the American College
of Cardiologists) at Texas Cardiac Arrhythmia. “Diagnosing and
managing sleep apnea is an essential component of cardiac care
pathways that can improve patient outcomes, but many patients
neither have access nor are able to manage the burden of spending a
night at a sleep center. Additionally, many cardiology centers do
not have the resources or infrastructure to offer home sleep apnea
testing directly to their patients. The collaboration between
Itamar Medical and BioTel Heart addresses both of these barriers by
allowing more cardiology centers to offer home sleep apnea testing
to their patients. Cardiologists’ ability to integrate Total Sleep
Solution into routine care strategies is an excellent option when
managing patients with sleep apnea.” Dr. Horton is a
board-certified cardiac electrophysiologist. He played a pivotal
role in developing the WatchPAT HST program and was among the first
cardiologists to implement the BioTel Heart solution using WatchPAT
for fast and accurate diagnosis of sleep apnea.
About BioTelemetry, Inc. and BioTel
HeartBioTelemetry, Inc. is the leading remote medical
technology company focused on delivery of health information to
improve quality of life and reduce cost of care. The company
provides remote cardiac monitoring, remote blood glucose
monitoring, centralized core lab services for clinical trials and
original equipment manufacturing that serves both healthcare and
clinical research customers. BioTel Heart is a preeminent
provider of remote patient monitoring, processing over four billion
heartbeats per day and monitoring over one million patients each
year. It is the pioneer in remote patient monitoring,
revolutionizing healthcare with its suite of cardiac monitoring
devices. More information can be found at www.gobio.com.
About Itamar Medical
Ltd. Itamar Medical is engaged in research,
development, sales and marketing of non-invasive medical devices
for the diagnosis of respiratory sleep disorders with a focus on
the cardiology market. The Company offers a Total Sleep Solution™
to help physicians provide comprehensive sleep apnea management in
a variety of clinical environments to optimize patient care and
reduce healthcare costs. Its flagship PAT-based product, the
WatchPAT™ device, is a home-use diagnostic device for sleep
breathing disorders. It also offers the EndoPAT™ system, an
FDA-cleared device to test endothelial dysfunction and to evaluate
the risk of heart disease and other cardiovascular diseases. Itamar
Medical is a public company traded on the Nasdaq and on the Tel
Aviv Stock Exchanges, and is based in Caesarea, Israel with U.S.
headquarters based in Atlanta, GA. For additional information visit
www.itamar-medical.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and other applicable securities laws.
Statements preceded by, followed by, or that otherwise include the
words "believes", "expects", "anticipates", "intends", "estimates",
"plans", and similar expressions or future or conditional verbs
such as "will", "should", "would", "may" and "could" are generally
forward-looking in nature and not historical facts. For example,
when we discuss potential outcomes and growth opportunities which
may arise out of the collaboration between Itamar Medical and
BioTelemetry, we are using forward-looking statements. Because such
statements deal with future events, they are subject to various
risks, uncertainties and assumptions, including events and
circumstances out of Itamar Medical's and/or BioTelemetry's control
and actual results, expressed or implied by such forward-looking
statements, could differ materially from Itamar Medical's current
expectations. Factors that could cause or contribute to such
differences include, but are not limited to, risks, uncertainties
and assumptions discussed from time to time by Itamar Medical
and/or BioTelemetry in reports filed with, or furnished to, the
U.S. Securities and Exchange Commission (“SEC”) (and also the
Israel Securities Authority (“ISA”), in the case of Itamar
Medical), including the Companies latest Annual Reports which are
on file with the SEC (and the ISA, in the case of Itamar Medical).
Except as otherwise required by law, neither Itamar Medical nor
BioTelemetry undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
The contents of any website of hyperlinks mentioned
in this press release are for informational purposes only and the
contents thereof are not part of this press release nor is it
incorporated herein by reference.
Itamar Medical Company
ContactItamar Medical Ltd.Shy BassonChief Financial
OfficerPhone: +972-4-617-7700bshy@itamar-medical.com
Itamar Medical Investor Relations Contact
(U.S.)Lazar Partners Ltd.David CareyPhone:
212-867-1762dcarey@lazarpartners.com
BioTelemetry, Inc.Heather C.
GetzInvestor RelationsExecutive Vice President, Chief Financial
Officer800-908-7103investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2024 to Jun 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2023 to Jun 2024